Seattle Genetics, Inc.  

(Public, NASDAQ:SGEN)   Watch this stock  
Find more results for sgen
36.44
-0.35 (-0.95%)
Nov 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 36.34 - 37.50
52 week 30.80 - 55.99
Open 36.93
Vol / Avg. 389,460.00/1.23M
Mkt cap 4.56B
P/E     -
Div/yield     -
EPS -0.53
Shares 123.89M
Beta 1.28
Inst. own 103%
Feb 9, 2015
Q4 2014 Seattle Genetics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 11, 2014
Seattle Genetics Inc at Credit Suisse Healthcare Conference - Webcast
Oct 30, 2014
Q3 2014 Seattle Genetics Inc Earnings Call - Webcast
Oct 30, 2014
Q3 2014 Seattle Genetics Inc Earnings Release
Sep 29, 2014
Seattle Genetics ADCETRIS phase 3 AETHERA clinical trial top-line results Conference Call - Webcast
Sep 9, 2014
Seattle Genetics Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -20.52% -23.22%
Operating margin -20.60% -23.35%
EBITD margin - -20.15%
Return on average assets -13.17% -13.09%
Return on average equity -27.69% -27.40%
Employees 582 -
CDP Score - -

Address

21823 30th Dr SE
BOTHELL, WA 98021-3907
United States - Map
+1-425-5274000 (Phone)
+1-425-5274001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (s ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology.

Officers and directors

Clay B. Siegall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Todd E. Simpson Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Eric L. Dobmeier Chief Operating Officer, Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Christopher S. Boerner Ph.D. Executive Vice President - Commercial
Age: 43
Bio & Compensation  - Reuters
Jonathan Drachman M.D. Chief Medical Officer and Executive Vice President, Research and Development
Age: 52
Bio & Compensation  - Reuters
Vaughn B. Himes Ph.D. Executive Vice President - Technical Operations, Process Sciences
Age: 53
Bio & Compensation  - Reuters
Kirk Schumacher Senior Vice President - Legal Affairs and Compliance, General Counsel
Bio & Compensation  - Reuters
Charles R. Romp Senior Vice President - Sales
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Lead Independent Director
Age: 45
Bio & Compensation  - Reuters
John A. Orwin Director
Age: 49
Bio & Compensation  - Reuters